Share this article

print logo

Roswell funding to aid continuing tobacco research

Roswell Park Cancer Institute during the next nine years is expected to receive $17.7 million as part of the Population Assessment of Tobacco and Health (PATH) Study, a long-standing effort to document and interpret tobacco use in the United States.

Funding will come from the National Institutes of Health and U.S. Food and Drug Administration. The study will be conducted by Westat of Rockville, Md., with Roswell Park continuing as scientific lead and Andrew Hyland, chairman of the Roswell Department of Health Behavior, serving as principal investigator.


Read a WNY Refresh story about strategies to quit smoking here.


The PATH study began collecting data in September 2013 and includes the largest group of tobacco users to be studied over time. Research will continue to offer insight into changes in tobacco product use; perceptions of harm from using new and emerging tobacco products; cessation efforts; analysis of biomarkers of tobacco related diseases; consumer perceptions of risk associated with public health outcomes; tobacco use patterns among demographic groups; and the influence of tobacco marketing on current, former and never tobacco users.

The research will continue to provide information to inform FDA regulatory considerations.

“The PATH Study will continue to be a vital resource offering scientific-based data to inform regulatory policy on tobacco use in a rapidly changing tobacco product marketplace,” Hyland said in a news release. “This study provides a unique and much-needed long-term approach to understanding tobacco use behaviors and to impacting those behaviors to reduce the toll of tobacco on the health of Americans.”

Other scientific partners are the Truth Initiative; University of Waterloo, Ont.; Moores Cancer Center at the University of California; Dartmouth-Hitchcock Norris Cotton Cancer Center; Rutgers University; Masonic Cancer Center at the University of Minnesota; and Medical University of South Carolina.

There are no comments - be the first to comment